<unk>  is used to treat infants with DiGeorge syndrome, which results in an absent or hypoplastic<unk> , in turn causing problems with the immune system's T-cell mediated response. It is used in people with complete DiGeorge anomaly, which are entirely athymic. This subgroup represents less than 1% of DiGeorge syndrome patients. Nezelof syndrome is another<unk> -related disease where it can be used. Co-transplantation with other organs In the 2000s, promising animal experiments into transplanting thymic tissue and another organ at the same time were carried out, in order to improve the recipient's tolerance of the transplanted organ, and to reduce the need for immunosuppressing drugs like tacrolimus. Such trials have been performed with kidney and heart transplants, drastically extending the time the animals were surviving without immunosuppressing drugs. The first human heart-and-thymus co-transplantation was performed on Easton Sinnamon in 2022, a newborn who suffered from both a lack of T cells, and a serious heart defect. Depending on the development, it is planned to wean him off immunosuppressant drugs, but it remains to be seen whether the same technique is viable in adults, as they lack a<unk> , with the bone marrow taking over T cell production.
Thymus transplantation
Spleen transplantation
Autologous immune enhancement therapy
Thymectomy
Syngeneic stem cell transplantation
Donor lymphocyte infusion
Stem-cell therapy
Organ transplantation